Cervical Cancer Clinical Trial
— ADSOfficial title:
Alternate Dosing Schedules Study for HPV Vaccine
Verified date | October 2014 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this study was to determine if delayed dosing of recombinant human
papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls
elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as
measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine
delivered according to the recommended dosing schedule.
This was a prospective observational study of healthy 9-18 year old female patients
receiving either a second or third dose of HPV vaccine as part of their well child care.
Immune responses to HPV types 6, 11, 16 and 18 were measured both before and 1 month after
the third dose of HPV vaccine with the purpose of comparing the immune responses to HPV
vaccine when administered at naturally occurring longer dosing intervals to the immune
response to HPV vaccine when administered as routinely recommended.
In addition, girls receiving a 3rd dose of HPV vaccine as well as concomitantly administered
vaccines by injection were randomized to receive either the HPV vaccine first or their
concomitantly administered vaccines first. Pain following vaccination was assessed in each
arm using the Faces Pain Scale - Revised.
Please note: This record refers only to the observational portion of the study. Please refer
to NCT00862810 for the results of the randomized portion of the study.
Status | Completed |
Enrollment | 331 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 9 Years to 18 Years |
Eligibility |
Inclusion Criteria: 1. A healthy, medically well female between the ages of 9 - 18 years. (Must be between 9 years and younger than 19 years of age) at time of enrollment 2. Must be receiving either a 3rd dose of HPV vaccine (All Groups) or a 2nd dose of HPV vaccine (Group 2 only) - For Group 1 - EITHER 1) The second dose of HPV vaccine must not have been administered and it must be within the specified dosing interval for the second dose of HPV vaccine (> 90 days since the first dose of HPV vaccine) OR 2) The second dose of HPV vaccine must have been administered > 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose of HPV vaccine (> 60 days - < 180 days since the second dose of HPV) - For Group 2 - The second dose of HPV vaccine must have been administered > 30 days and < 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (> 180 days since the second dose of HPV) - For Group 3 - The second dose of HPV vaccine must have been administered > 30 days and < 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (> 60 days - < 180 days since the second dose of HPV) - For Group 4- The second dose of HPV vaccine must have been administered > 90 days after the first dose of HPV of HPV vaccine and it must be within the specified dosing interval for the third dose (> 180 days since the second dose of HPV) 3. Ability and willingness to participate in the study by providing written informed assent. Verbal assent is acceptable for subjects less than 12 years of age. 4. Parent/guardian provides informed consent 5. Anticipated ability and willingness to complete all study visits and evaluations Exclusion Criteria: 1. Unable to comply with the study protocol 2. Receipt of three or more doses of HPV vaccine or receipt of doses of HPV vaccine outside the pre-specified time windows 3. Receipt of blood and or blood products (including immunoglobulin) in the past 3 months or anticipated receipt during the study period 4. Receipt of a live virus vaccine (varicella virus containing vaccine, any measles, mumps, or rubella virus containing vaccine such as MMR, or yellow fever vaccine but not including live attenuated influenza virus vaccine) within 4 weeks of receipt of the 3rd dose of HPV vaccine or anticipated receipt of a live virus vaccine within 4 weeks after the 3rd dose of HPV vaccine 5. History of any physical, mental, or developmental disorder that study personnel believe may hinder a participant's ability to comply with the study requirements 6. History of malignancy or confirmed or suspected immunodeficient condition such as HIV infection 7. Receipt of or history of receipt of any medications or treatments that affect the immune system, such as immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity since six months prior to the first HPV vaccine dose. Receipt of long-term (greater than or equal to 2 weeks) potentially immunosuppressive corticosteroid use within six months prior to HPV vaccine dose 1 and enrollment or anticipated receipt during the study period. Specifically, potentially immunosuppressive corticosteroids are any parenteral corticosteroid, high dose (>800 mcg/day) beclomethasone dipropionate or equivalent medication. Nasal and topical steroids are allowed. 8. Current or former participation in HPV vaccine related research. 9. Receipt of an investigational or alternate HPV vaccine |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Chapel Hill Pediatrics | Chapel Hill | North Carolina |
United States | Duke Children's Primary Care | Durham | North Carolina |
United States | Durham Pediatrics | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | Centers for Disease Control and Prevention |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HPV 6 GMT | Geometric mean titer (GMT) of antibody to HPV type 6 | 1 month following 3rd dose of HPV vaccine | No |
Primary | HPV 11 GMT | Geometric mean titer (GMT) of antibody to HPV type 11 | 1 month following 3rd dose of HPV vaccine | No |
Primary | HPV 16 GMT | Geometric mean titer (GMT) of antibody to HPV type 16 | 1 month following 3rd dose of HPV vaccine | No |
Primary | HPV 18 GMT | Geometric mean titer (GMT) of antibody to HPV type 18 | 1 month following 3rd dose of HPV vaccine | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |